(via TheNewswire)

Vancouver, British Columbia – TheNewswire - 3 June, 2026 – Helix BioPharma Corp. (TSX: “ HBP ”, OTC PINK: “ HBPCF ”, FRANKFURT: “ HBP0 ”) (“ Helix ” or the “ Company ”), a clinical-stage oncology company shaping a near future where today’s hard-to-treat cancers are vincible, announces that it has closed a non-brokered private placement (the “ Offering ”) of unsecured convertible debentures of the Company (each, a “ Convertible Debenture ”). The Company issued 3,673 Convertible Debentures for aggregate gross proceeds of C$3,673,000 pursuant to the Offering.

The principal amount and any unpaid accrued interest of the Convertible Debentures will be due and payable 14 months from the closing date of the private placement (the “ Maturity Date ”). Each Convertible Debenture will bear interest at 25.00% per annum, calculated on a simple interest basis. If the Convertible Debentures are not repaid on or prior to the Maturity Date, the outstanding principal amount of the Convertible Debentures may be convertible by the holder on the Maturity Date into common shares in the capital of the Company (each, a “ Share ”) at a price of C$1.42 per Share, being the market price of the Shares as of the price reservation date, less the permitted 20% discount in accordance with TSX policies (the “ Conversion Price ”). If the Convertible Debentures are not repaid on or prior to the Maturity Date, any accrued but unpaid interest of the Convertible Debentures may be convertible by the holder on the Maturity Date into Shares at a conversion price of the greater of: (i) the Conversion Price; and (ii) the volume weighted average trading price of the Shares listed on TSX during the five (5) trading days immediately preceding the relevant date, less the TSX permitted discount (the “ Interest Conversion Price ”).

The proceeds from the Offering are expected to be used for general working capital purposes as well as advancement of the Company’s drug development programs. No finder’s fees were paid in connection with the Offering.

The Convertible Debentures and any Shares issuable thereunder are subject to a statutory four-month hold period commencing on the closing date of the Offering.

About Helix BioPharma Corp.

Helix is an oncology company that innovates from strength to bring near-term solutions for today’s hardest-to-treat cancers. The Company’s pipeline is led by Tumor Defense Breaker™ L DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today’s front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix’s next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery. The Company also advances two pre-IND candidates: (i) LEUMUNA™, an oral immune checkpoint modulator aimed at achieving durable remission in post-transplant leukemia relapse, and (ii) GEMCEDA™, a first-in-class oral gemcitabine prodrug with bioavailability on a par with IV, designed to expand treatment options for advanced cancers.

The Shares of Helix are listed on TSX (HBP), OTC PINK (HBPCF), and FWB (HBP0). For more information, please visit: https://www.helixbiopharma.com/

For more information, please contact:

Helix BioPharma Corp.

789 West Pender Street, Suite 480

Vancouver, BC V6C 1H2

Tel: +1 857 208 7687

Thomas Mehrling, MD, PhD, Chief Executive Officer

corporate@helixbiopharma.com

Tel: 604-428-7050

Jacek Antas, Director

corporate@helixbiopharma.com

Forward-Looking Statements and Risks and Uncertainties

This news release contains forward-looking statements and information (collectively, “forward looking statements”) within the meaning of applicable Canadian securities laws. Forward-looking statements are statements and information that are not historical facts but instead include statements regarding plans, goals, objectives, intentions and expectations with respect to the Company’s Offering, future business, operations, research and development, including the Company’s activities relating to DOS47, LR 09 and GEMCEDA. Forward-looking statements can further be identified by the use of forward-looking terminology such as “will”, “plans”, “expects”, or the negative thereof or any other variations thereon or comparable terminology referring to future events or results, or that events or conditions “will”, “may”, “could”, or “should” occur or be achieved, or comparable terminology referring to future events or results.

Forward-looking statements are statements about the future and are inherently uncertain and are necessarily based upon a number of estimates and assumptions that are also uncertain. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Forward-looking statements are intended to provide information about management’s current plans and expectations regarding future operations and may not be appropriate for other purposes. Certain material factors, estimates or assumptions have been applied in making forward-looking statements in this news release. The Company’s actual results could differ materially from those anticipated in the forward-looking statements contained in this news release as a result of numerous known and unknown risks and uncertainties, including the risk factors discussed in the Company’s continuous disclosure record filed under the Company’s profile on SEDAR+ at www.sedarplus.ca from time to time. Forward-looking statements and information are based on the beliefs, assumptions, opinions and expectations of Helix’s management on the date of this new release, and the Company does not assume any obligation to update any forward-looking statement or information should those beliefs, assumptions, opinions or expectations, or other circumstances change, except as required by law.

_________________

Copyright (c) 2026 TheNewswire - All rights reserved.